Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): A clinicopathological study from the European MCL Network

British Journal of Haematology

Volumn 131, Issue 1, 2005, Pages 29-38

  Tiemann, Markus ^a   Schrader, Carsten ^a   Klapper, Wolfram ^a   Dreyling, Martin H ^b   Campo, Elias ^c   Norton, Andrew ^d   Berger, Francoise ^e   Kluin, Philip ^f   Ott, German ^g   Pileri, Stephano ^h   Pedrinis, Ennio ^c   Feller, Alfred C ⁱ   Merz, Hartmut ⁱ   Janssen, Dirk ^a   Hansmann, Martin L ^j   Van Krieken, Han ^k   Möller, Peter ^l   Stein, Harald ^m   Unterhalt, Michael ^b   Hiddemann, Wolfgang ^b   Parwaresch, Reza ^a   more..

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Department of Haematopathology ^*  (Switzerland)

^d BARTS HEALTH NHS TRUST   (United Kingdom)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f LEIDEN UNIVERSITY   (Netherlands)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^j GOETHE UNIVERSITY   (Germany)

^k RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^l UNIVERSITY OF ULM   (Germany)

^m HUMBOLDT UNIVERSITY   (Germany)

more..

Author keywords

Cytology; Growth pattern; Ki 67 index; Mantle cell lymphoma; Mitotic index

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; CLINICAL TRIAL; MIDDLE AGED; MITOSIS INDEX; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; CLINICAL TRIALS; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MITOTIC INDEX; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 27744523816     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05716.x     Document Type: Article

References (40)

1. Argatoff L.H. Connors J.M. Klasa R.J. Horsman D.E. Gascoyne R.D. ( 1997) Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood, 89, 2067 2078.
2. Bosch F. Lopez-Guillermo A. Campo E. Ribera J.M. Conde E. Piris M.A. Vallespi T. Woessner S. Montserrat E. ( 1998) Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer, 82, 567 575.
3. Brittinger G. Bartels H. Common H. Duhmke E. Fulle H.H. Gunzer U. Gyenes T. Heinz R. Konig E. Meusers P. ( 1984) Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematological Oncology, 2, 269 306.
4. Campo E. Raffeld M. Jaffe E.S. ( 1999) Mantle-cell lymphoma. Seminars in Hematology, 36, 115 127.
5. Cordell J.L. Falini B. Erber W.N. Ghosh A.K. Abdulaziz Z. MacDonald S. Pulford K.A. Stein H. Mason D.Y. ( 1984) Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). Journal of Histochemistry & Cytochemistry, 32, 219 229.
6. Decaudin D. Bosq J. Munck J.N. Bayle C. Koscielny S. Boudjemaa S. Bennaceur A. Venuat A.M. Naccache P. Bendahmane B. Ribrag V. Carde P. Pico J.L. Hayat M. ( 1997) Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 cases. Leukemia & Lymphoma, 26, 539 550.
7. Dreyling M. Lenz G. Hoster E. Van Hoof A. Gisselbrecht C. Schmits R. Metzner B. Truemper L. Reiser M. Steinhauer H. Boiron J.M. Boogaerts M.A. Aldaoud A. Silingardi V. Kluin-Nelemans H.C. Hasford J. Parwaresch R. Unterhalt M. Hiddemann W. ( 2004) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma - results of a prospective randomized trial of the European MCL network. Blood, 105, 2677 2684.
8. Fisher R.I. Dahlberg S. Nathwani B.N. Banks P.M. Miller T.P. Grogan T.M. ( 1995) A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood, 85, 1075 1082.
9. Gerdes J. Lemke H. Baisch H. Wacker H.H. Schwab U. Stein H. ( 1984a) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. Journal of Immunology, 133, 1710 1715.
10. Gerdes J. Dallenbach F. Lennert K. Lemke H. Stein H. ( 1984b) Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematological Oncology, 2, 365 371.
11. Hsu S.M. Raine L. Fanger H. ( 1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. Journal of Histochemistry & Cytochemistry, 29, 577 580.
12. Jaffe E.S. Harris N.L. Stein H. Vardiman J.W. ( 2001) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon.
13. Jares P. Campo E. Pinyol M. Bosch F. Miquel R. Fernandez P.L. Sanchez-Beato M. Soler F. Perez-Losada A. Nayach I. Mallofre C. Piris M.A. Montserrat E. Cardesa A. ( 1996) Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. American Journal of Pathology, 148, 1591 1600.
14. Kreipe H. Wacker H.H. Heidebrecht H.J. Haas K. Hauberg M. Tiemann M. Parwaresch R. ( 1993) Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. American Journal of Pathology, 142, 1689 1694.
15. Lardelli P. Bookman M.A. Sundeen J. Longo D.L. Jaffe E.S. ( 1990) Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. American Journal of Surgical Pathology, 14, 752 763.
16. Laszlo T. Matolcsy A. ( 1999) Blastic transformation of mantle cell lymphoma: genetic evidence for a clonal link between the two stages of the tumour. Histopathology, 35, 355 359.
17. Lenz G. Dreyling M. Hiddemann W. ( 2004a) Mantle cell lymphoma: established therapeutic options and future directions. Annals of Hematology, 83, 71 77.
18. Lenz G. Dreyling M. Schiegnitz E. Haferlach T. Hasford J. Unterhalt M. Hiddemann W. ( 2004b) Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. Journal of Clinical Oncology, 22, 4926 4933.
19. Majlis A. Pugh W.C. Rodriguez M.A. Benedict W.F. Cabanillas F. ( 1997) Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. Journal of Clinical Oncology, 15, 1664 1671.
20. Medeiros L.J. Van Krieken J.H. Jaffe E.S. Raffeld M. ( 1990) Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood, 76, 2086 2090.
21. Meusers P. Engelhard M. Bartels H. Binder T. Fulle H.H. Gorg K. Gunzer U. Havemann K. Kayser W. Konig E. ( 1989) Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematological Oncology, 7, 365 380.
22. Ott M.M. Ott G. Kuse R. Porowski P. Gunzer U. Feller A.C. Muller-Hermelink H.K. ( 1994) The anaplastic variant of centrocytic lymphoma is marked by frequent rearrangements of the bcl-1 gene and high proliferation indices. Histopathology, 24, 329 334.
23. Ott G. Kalla J. Ott M.M. Schryen B. Katzenberger T. Muller J.G. Muller-Hermelink H.K. ( 1997) Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood, 89, 1421 1429.
24. Ott G. Kalla J. Hanke A. Muller J.G. Rosenwald A. Katzenberger T. Kretschmar R. Kreipe H. Muller-Hermelink H.K. ( 1998) The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological features. Leukemia & Lymphoma, 32, 55 63.
25. Pinyol M. Cobo F. Bea S. Jares P. Nayach I. Fernandez P.L. Montserrat E. Cardesa A. Campo E. ( 1998) p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood, 91, 2977 2984.
26. Pittaluga S. Wlodarska I. Stul M.S. Thomas J. Verhoef G. Cassiman J.J. Van D.B. De Wolf-Peeters C. ( 1995) Mantle cell lymphoma: a clinicopathological study of 55 cases. Histopathology, 26, 17 24.
27. Raty R. Franssila K. Joensuu H. Teerenhovi L. Elonen E. ( 2002) Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. European Journal of Haematology, 69, 11 20.
28. Rosenwald A. Wright G. Wiestner A. Chan W.C. Connors J.M. Campo E. Gascoyne R.D. Grogan T.M. Muller-Hermelink H.K. Smeland E.B. Chiorazzi M. Giltnane J.M. Hurt E.M. Zhao H. Averett L. Henrickson S. Yang L. Powell J. Wilson W.H. Jaffe E.S. Simon R. Klausner R.D. Montserrat E. Bosch F. Greiner T.C. Weisenburger D.D. Sanger W.G. Dave B.J. Lynch J.C. Vose J. Armitage J.O. Fisher R.I. Miller T.P. LeBlanc M. Ott G. Kvaloy S. Holte H. Delabie J. Staudt L.M. ( 2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 3, 185 197.
29. Schrader C. Meusers P. Brittinger G. Teymoortash A. Siebmann J.U. Janssen D. Parwaresch R. Tiemann M. ( 2004) Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia, 18, 1200 1206.
30. Solal-Celigny P. Roy P. Colombat P. White J. Armitage J.O. Arranz-Saez R. Au W.Y. Bellei M. Brice P. Caballero D. Coiffier B. Conde-Garcia E. Doyen C. Federico M. Fisher R.I. Garcia-Conde J.F. Guglielmi C. Hagenbeek A. Haioun C. LeBlanc M. Lister A.T. Lopez-Guillermo A. McLaughlin P. Milpied N. Morel P. Mounier N. Proctor S.J. Rohatiner A. Smith P. Soubeyran P. Tilly H. Vitolo U. Zinzani P.L. Zucca E. Montserrat E. ( 2004) Follicular lymphoma international prognostic index. Blood, 104, 1258 1265.
31. Swerdlow S.H. Habeshaw J.A. Murray L.J. Dhaliwal H.S. Lister T.A. Stansfeld A.G. ( 1983) Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. American Journal of Pathology., 113, 181 197.
32. Tolksdorf G. Stein H. Lennert K. ( 1980) Morphological and immunological definition of a malignant lymphoma derived from germinal-centre cells with cleaved nuclei (centrocytes). British Journal of Cancer, 41, 168 182.
33. Van Den Berghe H. Parloir C. David G. Michaux J.L. Sokal G. ( 1979) A new characteristic karyotypic anomaly in lymphoproliferative disorders. Cancer, 44, 188 195.
34. Velders G.A. Kluin-Nelemans J.C. De Boer C.J. Hermans J. Noordijk E.M. Schuuring E. Kramer M.H. Van Deijk W.A. Rahder J.B. Kluin P.M. van Krieken J.H. ( 1996) Mantle-cell lymphoma: a population-based clinical study. Journal of Clinical Oncology., 14, 1269 1274.
35. Weisenburger D.D. Armitage J.O. ( 1996) Mantle cell lymphoma - an entity comes of age. Blood, 87, 4483 4494.
36. Weisenburger D.D. Nathwani B.N. Diamond L.W. Winberg C.D. Rappaport H. ( 1981) Malignant lymphoma, intermediate lymphocytic type: a clinicopathologic study of 42 cases. Cancer, 48, 1415 1425.
37. Weisenburger D.D. Kim H. Rappaport H. ( 1982) Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma. Cancer, 49, 1429 1438.
38. Williams M.E. Meeker T.C. Swerdlow S.H. ( 1991) Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: analysis with multiple breakpoint probes. Blood, 78, 493 498.
39. Zoldan M.C. Inghirami G. Masuda Y. Vandekerckhove F. Raphael B. Amorosi E. Hymes K. Frizzera G. ( 1996) Large-cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome. British Journal of Haematology, 93, 475 486.
40. Zucca E. Stein H. Coiffier B. ( 1994) European Lymphoma Task Force (ELTF): report of the workshop on Mantle Cell Lymphoma (MCL). Annals of Oncology, 5, 507 511.